Products

DEP® irinotecan is a novel, patented nanoparticle formulation of SN-38, the active metabolite of irinotecan, delivered using Starpharma’s proprietary DEP® technology. DEP® irinotecan has shown a number of benefits compared to the original form of irinotecan, including significant improvements in anti-cancer efficacy and improved survival in multiple human cancer models. DEP® irinotecan is the third DEP® product to enter the clinic from Starpharma’s internal portfolio.

DEP® docetaxel is water-soluble and does not require surfactant such as polysorbate 80 for dissolution. Drug substance is readily manufactured at scale using standard chemistry under cGMP.

DEP® cabazitaxel is Starpharma’s detergent-free version of cancer drug, Jevtana®, which is marketed by Sanofi Aventis to treat advanced prostate cancer, and is also under clinical development for a range of other cancer types, including testicular, ovarian, breast, bladder, and head and neck.